Your browser is no longer supported. Please, upgrade your browser.
Settings
LGND Ligand Pharmaceuticals Incorporated daily Stock Chart
LGND [NASD]
Ligand Pharmaceuticals Incorporated
Index- P/E- EPS (ttm)-1.38 Insider Own4.10% Shs Outstand16.06M Perf Week-9.52%
Market Cap1.51B Forward P/E18.79 EPS next Y4.90 Insider Trans-2.66% Shs Float15.44M Perf Month-19.76%
Income-24.70M PEG- EPS next Q0.81 Inst Own- Short Float58.40% Perf Quarter-20.78%
Sales126.40M P/S11.98 EPS this Y432.60% Inst Trans-1.84% Short Ratio34.29 Perf Half Y26.36%
Book/sh43.29 P/B2.13 EPS next Y18.59% ROA-1.80% Target Price- Perf Year-12.05%
Cash/sh49.26 P/C1.87 EPS next 5Y22.50% ROE-3.30% 52W Range57.24 - 127.80 Perf YTD-11.71%
Dividend- P/FCF54.45 EPS past 5Y124.30% ROI45.50% 52W High-30.95% Beta1.45
Dividend %- Quick Ratio29.40 Sales past 5Y13.30% Gross Margin86.20% 52W Low54.18% ATR4.19
Employees115 Current Ratio29.50 Sales Q/Q65.60% Oper. Margin-3.50% RSI (14)21.67 Volatility4.93% 3.93%
OptionableYes Debt/Eq0.00 EPS Q/Q279.50% Profit Margin-19.50% Rel Volume1.15 Prev Close92.08
ShortableYes LT Debt/Eq0.65 EarningsAug 03 BMO Payout- Avg Volume262.90K Price88.25
Recom2.30 SMA20-12.72% SMA50-20.89% SMA200-13.09% Volume122,944 Change-4.16%
Mar-24-20Downgrade Argus Buy → Hold
Mar-10-20Initiated Guggenheim Neutral
Feb-06-20Initiated The Benchmark Company Buy $135
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
May-03-19Reiterated H.C. Wainwright Buy $254 → $214
Mar-06-19Reiterated H.C. Wainwright Buy $281 → $254
Oct-29-18Upgrade ROTH Capital Neutral → Buy
Oct-02-18Reiterated H.C. Wainwright Buy $270 → $280
Sep-11-18Reiterated Argus Buy $260 → $300
Aug-17-18Initiated Goldman Neutral $256
Aug-08-18Downgrade ROTH Capital Buy → Neutral
Jun-21-18Initiated Argus Buy $260
Dec-27-17Reiterated H.C. Wainwright Buy $163 → $169
Sep-05-17Resumed H.C. Wainwright Buy $150
Oct-05-16Reiterated H.C. Wainwright Buy $146 → $160
Aug-05-16Downgrade Deutsche Bank Hold → Sell $104 → $110
Mar-11-16Initiated Sidoti Buy
Mar-03-16Initiated H.C. Wainwright Buy $146
Dec-18-15Reiterated ROTH Capital Buy $144 → $146
Sep-18-20 07:16AM  
Sep-10-20 08:00AM  
Sep-09-20 11:40AM  
Sep-02-20 11:30AM  
Sep-01-20 04:02PM  
Aug-31-20 09:00AM  
Aug-25-20 04:15PM  
Aug-24-20 11:40AM  
08:30AM  
Aug-20-20 10:46AM  
Aug-12-20 10:32AM  
Aug-11-20 01:10PM  
08:20AM  
06:22AM  
Aug-10-20 05:36PM  
Aug-07-20 11:40AM  
08:30AM  
Aug-04-20 11:01AM  
Aug-03-20 02:10PM  
02:00PM  
08:55AM  
07:30AM  
Aug-02-20 11:08AM  
Jul-16-20 04:28PM  
Jul-13-20 07:51AM  
Jul-12-20 04:16PM  
Jul-08-20 10:00AM  
Jul-03-20 11:40AM  
Jun-29-20 12:48PM  
11:44AM  
09:12AM  
Jun-17-20 11:40AM  
Jun-15-20 08:30AM  
Jun-08-20 02:04PM  
Jun-05-20 11:31AM  
Jun-04-20 10:45PM  
Jun-03-20 06:43PM  
Jun-01-20 04:53PM  
11:40AM  
May-29-20 08:00AM  
May-28-20 04:22PM  
04:08PM  
May-22-20 08:58AM  
May-14-20 11:50AM  
May-07-20 04:00PM  
11:40AM  
11:11AM  
May-06-20 05:45PM  
04:01PM  
May-03-20 03:37PM  
Apr-29-20 12:34PM  
Apr-22-20 08:30AM  
Apr-17-20 08:00AM  
Apr-09-20 10:51AM  
Apr-08-20 12:10PM  
Apr-07-20 12:16PM  
Apr-06-20 07:00AM  
Apr-02-20 04:02PM  
Mar-18-20 02:29PM  
Mar-10-20 08:00AM  
Mar-09-20 01:30PM  
Mar-07-20 11:30AM  
Mar-02-20 08:00AM  
Feb-27-20 08:00AM  
Feb-19-20 08:00PM  
06:30AM  
Feb-17-20 11:12AM  
Feb-11-20 04:14PM  
Feb-07-20 10:49AM  
Feb-06-20 06:35PM  
04:01PM  
Feb-03-20 08:30AM  
Jan-13-20 04:02PM  
Jan-09-20 02:47PM  
Jan-08-20 11:04AM  
Jan-06-20 11:40AM  
Dec-23-19 08:30AM  
Dec-20-19 05:03PM  
Dec-12-19 10:41PM  
Dec-06-19 08:00AM  
Dec-05-19 11:31AM  
Dec-02-19 08:30AM  
Nov-19-19 07:16AM  
Nov-12-19 08:30AM  
Nov-08-19 08:30AM  
Nov-07-19 08:30AM  
Nov-06-19 09:33AM  
Nov-05-19 06:15PM  
04:02PM  
04:01PM  
Oct-29-19 10:32AM  
Oct-25-19 10:13AM  
Oct-22-19 04:01PM  
Oct-15-19 09:00AM  
Oct-10-19 10:08AM  
Oct-03-19 08:00AM  
Sep-23-19 10:01AM  
Sep-13-19 08:42AM  
Sep-12-19 06:41AM  
Aug-29-19 09:31AM  
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOEHR MATTHEW WPresident and COOAug 24Option Exercise21.92781,710155,491Aug 25 07:10 PM
FOEHR MATTHEW WPresident and COOAug 24Sale110.89788,649155,413Aug 25 07:10 PM
FOEHR MATTHEW WPresident and COOAug 21Option Exercise20.388,015163,338162,638Aug 25 07:10 PM
FOEHR MATTHEW WPresident and COOAug 21Sale112.887,225815,541155,413Aug 25 07:10 PM
HIGGINS JOHN LChief Executive OfficerJul 07Option Exercise70.014,315302,098204,571Jul 09 04:28 PM
Berkman Charles SSVP, Gen. Counsel & SecretaryJun 04Sale118.5911,1461,321,77540,877Jun 05 04:07 PM
FOEHR MATTHEW WPresident and COOMar 13Option Exercise21.922,00043,840157,449Mar 13 06:33 PM
FOEHR MATTHEW WPresident and COOFeb 27Option Exercise15.898,931141,941160,968Feb 27 08:35 PM
FOEHR MATTHEW WPresident and COOFeb 27Sale110.007,225794,750153,743Feb 27 08:35 PM
FOEHR MATTHEW WPresident and COOFeb 14Option Exercise14.477,225104,546163,454Feb 18 05:09 PM
FOEHR MATTHEW WPresident and COOFeb 14Sale95.847,225692,467156,229Feb 18 05:09 PM
HIGGINS JOHN LChief Executive OfficerFeb 13Option Exercise9.9648,125479,325201,739Feb 18 05:11 PM
FOEHR MATTHEW WPresident and COOFeb 13Option Exercise21.9249610,872148,833Feb 18 05:09 PM
FOEHR MATTHEW WPresident and COONov 12Option Exercise21.921,00121,942144,620Nov 13 04:07 PM